HBIO · Harvard Bioscience, Inc.

Performance Summary

Harvard Bioscience reported a difficult fiscal 2025 with revenues declining 8.1% to $86.5 million from $94.1 million in 2024. The company recorded a substantial net loss of $56.7 million, primarily driven by a $48.0 million goodwill impairment charge recognized in the first quarter of 2025. Despite the significant loss, the company generated positive operating cash flow of $6.7 million, an improvement from $1.4 million in 2024. The balance sheet shows total assets of $80.1 million, with cash and equivalents of $8.6 million and total debt of $35.9 million. Stockholders' equity stands at $13.7 million, reflecting the impact of accumulated losses.

Revenue Analysis

Revenue decreased by $7.5 million year-over-year, primarily due to softening worldwide demand from distributors, contract research organizations (CROs), and academic medical research institutions. Foreign currency exchange rates had a favorable effect of $1.2 million on revenues during the year. The company's revenue mix shifted slightly, with the Cellular and Molecular (CMT) segment representing 46% of revenues (down from 49% in 2024) and the Preclinical segment representing 54% (up from 51% in 2024). Third-party distribution accounted for 13% of revenues, up from 12% in the prior year. Direct sales to end-users represented approximately 61% of revenues, while distributor sales accounted for 39%.

Margins & Profitability

Gross margin declined slightly to 57.7% from 58.2% in the prior year, primarily due to under-absorption of fixed manufacturing overhead costs resulting from decreased revenues, partially offset by a better mix of high-margin products and lower labor costs. Operating expenses totaled $98.5 million, including the significant goodwill impairment charge. Excluding this impairment, operating expenses decreased year-over-year due to cost reduction initiatives. Sales and marketing expenses decreased 13.5% to $19.2 million, general and administrative expenses decreased 17.5% to $17.7 million, and research and development expenses decreased 15.2% to $8.8 million.

Cash Flow & Balance Sheet

The company generated $6.7 million in operating cash flow, driven by non-cash adjustments including the $48.0 million goodwill impairment, $4.2 million amortization of intangible assets, and $1.9 million stock-based compensation. Working capital changes contributed positively, with inventory decreasing by $2.9 million and accounts payable increasing by $2.3 million. Investing activities used $1.9 million primarily for capital expenditures and software development. Financing activities used $1.3 million, with net borrowing of $40.0 million under the new credit facility offset by debt repayments and issuance costs. The company ended the year with $8.6 million in cash and $35.9 million in long-term debt.

Outlook

The company has implemented several strategic initiatives to improve its position. The December 2025 debt refinancing eliminated going concern doubts and provided improved covenant compliance. Project Viking, a manufacturing consolidation initiative announced in January 2026, is expected to deliver approximately $3 million in cost savings in 2027 and $4 million annually beginning in 2028, with pre-tax restructuring charges estimated at $3.4-$4.4 million. The company continues to focus on its four strategic pillars: leading the translational bridge, new product introduction pipeline, consumables revenue expansion, and operational excellence. However, the company faces risks including Nasdaq listing compliance issues, competitive pressures, and dependence on pharmaceutical and biotechnology industry spending.